<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12034158
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     05
    </month>
    <day>
     29
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     10
    </month>
    <day>
     16
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1388-9842
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       4
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Jun
       </month>
      </pubdate>
     </journalissue>
     <title>
      European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology
     </title>
     <isoabbreviation>
      Eur. J. Heart Fail.
     </isoabbreviation>
    </journal>
    <articletitle>
     Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.
    </articletitle>
    <pagination>
     <medlinepgn>
      321-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality and morbidity in patients with chronic heart failure. Carvedilol is an adrenoceptor antagonist, which inhibits beta(1)-, beta(2)-, and alpha(1)-adrenergic receptors. Carvedilol has additional metabolic and antioxidant properties. Metoprolol is a selective antagonist of beta(1)-adrenergic receptors. The carvedilol or metoprolol European trial (COMET) is the first study to investigate whether beta-blocking agents with differing pharmacological profiles exert different effects on morbidity and mortality in patients with chronic heart failure. 3029 patients from 15 different European countries were enrolled into COMET and will be followed until 1020 fatal events have been observed, unless the data and safety monitoring committee (DSMC) recommends early termination. The target dose for carvedilol is 25 mg bid and for metoprolol tartrate 50 mg bid. This manuscript outlines the rationale, design and possible outcomes of COMET.
     </abstracttext>
    </abstract>
    <affiliation>
     Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, Dovehouse Street, London, SW3 6LY, UK. p.poole-wilson@ic.ac.uk
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Poole-Wilson
      </lastname>
      <forename>
       Philip A
      </forename>
      <initials>
       PA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cleland
      </lastname>
      <forename>
       John G F
      </forename>
      <initials>
       JG
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Di Lenarda
      </lastname>
      <forename>
       Andrea
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hanrath
      </lastname>
      <forename>
       Peter
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Komajda
      </lastname>
      <forename>
       Michel
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Metra
      </lastname>
      <forename>
       Marco
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       J  Remme
      </lastname>
      <forename>
       Willem
      </forename>
      <initials>
       W
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Swedberg
      </lastname>
      <forename>
       Karl
      </forename>
      <initials>
       K
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Torp-Pedersen
      </lastname>
      <forename>
       Christian
      </forename>
      <initials>
       C
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     Netherlands
    </country>
    <medlineta>
     Eur J Heart Fail
    </medlineta>
    <nlmuniqueid>
     100887595
    </nlmuniqueid>
    <issnlinking>
     1388-9842
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adrenergic beta-Antagonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Carbazoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Propanolamines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      37350-58-6
     </registrynumber>
     <nameofsubstance>
      Metoprolol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      72956-09-3
     </registrynumber>
     <nameofsubstance>
      carvedilol
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adrenergic beta-Antagonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Carbazoles
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N" type="Geographic">
      Europe
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heart Failure
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Metoprolol
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Patient Selection
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Propanolamines
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Research Design
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      5
     </month>
     <day>
      30
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      10
     </month>
     <day>
      17
     </day>
     <hour>
      4
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      5
     </month>
     <day>
      30
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12034158
    </articleid>
    <articleid idtype="pii">
     S1388984202000259
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

